Patent SG-11201810327X-A (SG)
Title: Single domain serum albumin binding protein
Inventor: DUBRIDGE ROBERT B
IPC: C07K16/28
Filed: 2017-05-19
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011111111101 1111111101011111011010111010111111111111011111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0 WO 2017/201488 Al 23 November 2017 (23.11.2017) WIPO I PCT — (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) International Patent Classification: Mar, San Francisco, California 94121 (US). GUENOT, A61K 39/395 (2006.01) C07K 16/18 (2006.01) Jeanmarie; 45 Juniper Street, #3, San Francisco, California A61K 47/48 (2006.01) C07K 16/28 (2006.01) 94103 (US). International Application Number: (74) Agent: LIN, Clark Y.; Wilson Sonsini Goodrich & Rosati, PCT/US2017/033665 650 Page Mill Road, Palo Alto, California 94304 (US). International Filing Date: (81) Designated States (unless otherwise indicated, for every 19 May 2017 (19.05.2017) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, Priority Data: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 62/339,682 20 May 2016 (20.05.2016) US MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, Applicant: HARPOON THERAPEUTICS, INC. PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, [US/US]; 4000 Shoreline Court, Suite 250, South San Fran- SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, cisco, California 94080 (US). TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Inventors: DUBRIDGE, Robert B.; 825 Holly Road, (84) Designated States (unless otherwise indicated, for every Belmont, California 94002 (US). LEMON, Bryan D.; kind of regional protection available): ARIPO (BW, GH, 2493 Dell Ave., Mountain View, California 94043 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, AUSTIN, Richard J.; 1169 Guerrero St., San Francisco, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, California 94110 (US). EVNIN, Luke; 768 El Camino Del TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = Title: SINGLE DOMAIN C IS C 1 5 a) 0. : Disclosed herein robust aggregation profiles. according to the instant using such formulations are provided. (54) SERUM 10 ALBUMIN BINDING PROTEIN FIG. 2 Cross Reactivity of HSA Phage 10000 binding affinities, serum albumin binding herein and methods disclosed = = = = 1 - 0.1 ...,.., / / / I / / X I / • , ...,.. = = - = -0- HSA . 0 CSA --v- rHSA - 6 - rMSA = a single proteins thermal stability, domain - = 11 Ot Ot iv 1-1 0 N .---- (57) IN ,-1 and 0 protein N of Also disclosure. Pharmaceutical compositions comprising 10 100 1000 Ag Mass (ng) with improved comprising the binding are single domain serum albumins binding proteins described are multispecific binding proteins [Continued on next page] WO 2017/201488 Al MIDEDIM11110111111111111111111111111111111111111111111111111111110111110111111111111 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a))